Introduction
Although 60% of cases of extranodal non-Hodgkin's lymphoma arise in the head and neck-, primary orbital disease occurs infrequently2. 4 . As a consequence, even major oncology centres may only treat one case annually and experience in the management of this tumour is therefore limited and often anecdotal.
Between 1954 and 1980, 1600 patients with non-Hodgkin's lymphoma were treated at the Regional Radiotherapy Centre, Mount Vernon Hospital. Four hundred and thirty of these patients (27%) presented with primary extranodal disease which included 9 cases of orbital lymphoma (0.5%).
Patients and methods
The mean age of the 5 male and 4 female patients was 67 years (median 71 years) and ranged from 43 years to 82 years. Six patients presented with proptosis, 5 with swelling of the upper eyelid (Figures lA and B) and 4 with diplopia. The mean duration of symptoms was 7 months and ranged from 2 weeks to 12 months. In each case the diagnosis was confirmed pathologically.The mean period of follow-up was 90 months (range 5-187 months: median 87 months). 
Treatment
Local radiotherapy was given in every case using either orthovoltage (250 kV) or megavoltage (60CO or 5 MeV linear accelerator) equipment. Five patients were treated with a single direct field and 4 patients with a paired field arrangement designed to obtain a more homogeneous dose distribution throughout the treatment volume. The average field size was 5.5x5.5cm (range 4x4cm to 7x8cm). Although a variety of dose/fractionation schedules were used during the 26 year period, 7 patients received between 30 and 42 Gy in 3-4 weeks and the remaining 2 patients were treated to 20 and 63 Gy, respectively. The mean radiation dose was 37.2 Gy in 17 fractions over 25 days.
Results
In every case complete local regression of the tumour was seen following radiotherapy and no patients experienced a local relapse. Eight patients are now dead and the sole survivor, who was treated over 7 years ago, remains in complete remission. The overall 5 year survival was 89%. Two patients, both with grade 2 disease, died from lymphoma having relapsed below the diaphragm. Other causes of death included a cerebrovascular accident, myocardial infarction, bronchopneumonia and bronchial carcinoma.
Three relapses were reported. One patient developed cervical lymphadenopathy within 3 months of presentation and deteriorated rapidly; a postmortem revealed lymphomatous infiltration of the liver, spleen and adrenal glands. The second patient relapsed 7lh years after presentation and again developed widespread intra-abdominal disease which proved rapidly fatal. The final patient, who presented with diffuse well differentiated lymphocytic lymphoma, was diagnosed as having chronic lymphatic leukaemia 5 years after presentation; he survived a further 6lh years and died from bronchial carcinoma. The 5 year relapse free survival was 76%.
Two patients developed radiation cataracts 15 and 35 months after treatment and the former patient also complained of persistent epiphora. Each had been irradiated using megavoltage equipment to 36 and 40 Gy, respectively.
Discussion
Although primary non-Hodgkin's lymphoma of the orbit is only seen infrequently, an awareness of this diagnosis is important as the tumour is potentially curable.
The choice of treatment is primarily determined by the disease extent. Tumours which are confined to the orbit and immediately adjacent areas are suitable for irradiation but if several non-contiguous sites are involved, or the tumour has disseminated, chemotherapy will be required. An accurate assessment of the local disease and potential sites of distant involvement should therefore be performed prior to commencing therapy -a process which has been greatly facilitated by the advent of computed tomography and ultrasound.
Although in this series assessment of the abdomen relied primarily upon clinical examination, only 2 patients relapsed below the diaphragm, one of whom recurred 7 years after presentation. In contrast, therefore, to the more common sites of head and neck lymphoma10,11, this data and other reports 4, 12 suggest that stage IIIE and IV disease rarely arises in association with primary orbital lymphoma.
The prognosis of orbital lymphoma compares very favourably with other extranodal sites in the head and neck 1,uO.13-15. This may reflect the decreased incidence of advanced stage disease and the earlier presentation of patients in whom even a small retrobulbar mass may produce distressing symptoms. The incidence of the prognostically more favourable grade 1 histology is also relatively high in orbital lymphoma; for lymphocytic lymphoma (low grade), Calle et al. 13 reported a 5 year survival of 90% compared to 36% for lymphosarcoma or reticulum cell sarcoma (high grade). In this series both lymphoma related deaths occurred in patients with grade II histology and high grade histology was also present in both major relapses. Similar results have also been reported previously by Kim and Fayos12. Radiotherapy is effective local treatment for orbital non-Hodgkin's lymphoma1,4,12 and will be curative in a substantial number of patients. In a review of both nodal and extranodal grade 2 non-Hodgkin's lymphoma, Lamb et al. 16 reported that local response was dependent on the radiotherapy dose and only reached 100% for doses in excess of 4500 cGy. Using a schedule of 200cGy/day such a regimen would have a time, dose and fractionation factor (TDF) of 73. In this series 3 of the 4 patients with grade 2 histology received less than 36 Gy although the fractionation regimens used had TDF factors of 33, 59 and 64, respectively. For the whole series the mean radiation dose was 37.2 Gy (TDF 60). Kim and Fayos12 also reported no local recurrences in their series and although details of their fractionation regimens were not published, when treating with a single direct field the mean incident dose was 27 Gy given in 3-4 weeks (TDF 36-42). Franklin" treated patients with a single fraction of 8 Gy and also obtained a good local response although 70% of these patients experienced significant complications including radiation induced conjunctivitis and cataract formation.
Although the number of patients included in these 3 series are small, the excellent local control rates with relatively modest dose radiotherapy suggest that orbital lymphoma may be more radiosensitive than disease at other sites. The greater preponderance of low grade histological variants is undoubtedly relevant, but fails to totally explain these results. The minimum effective radiation dose for orbital lymphoma has yet to be determined and as the tumour has an excellent prognosis every effort should be made to minimize the morbidity.
The lens is most at risk from radiation damage. Even after fractionated treatment with doses as low as 350 cGy, cataract formation may occur. Although this complication is readily amenable to surgical correction, direct irradiation of the lens should be avoided whenever this is feasible without compromising treatment. Dysfunction of the lacrimal apparatus is rarely seen with less than 3000 cGy and retinal damage seldom occurs below 5000 cGy.
Both prophylactic nodal irradiation l 3 • l 7 and adjuvant chemotherapyl? have also been advocated as part of the routine management of orbital non-Hodgkin's lymphoma. However, the patients most at risk from relapse have high grade histology whose effective treatment entails the use of combination chemotherapy regimens such as CHOP (cyclophosphamide, adriamycin, prednisone, vincristine). Such treatment is associated with a significant morbidity, especially in the elderly, and the benefits of adjuvant therapy should therefore be clearly demonstrated prior to its routine application.
